AstraZeneca’s (AZN) “Buy” Rating Reaffirmed at Shore Capital

AstraZeneca (LON:AZN)‘s stock had its “buy” rating restated by investment analysts at Shore Capital in a note issued to investors on Thursday, Marketbeat Ratings reports.

Several other brokerages also recently commented on AZN. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a £110 ($143.19) price target on shares of AstraZeneca in a research report on Tuesday, September 3rd. JPMorgan Chase & Co. restated an “overweight” rating on shares of AstraZeneca in a report on Monday, September 16th. Finally, Berenberg Bank reiterated a “buy” rating and set a £150 ($195.26) price target on shares of AstraZeneca in a report on Monday, September 2nd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of £104.12 ($135.54).

AstraZeneca Price Performance

AZN stock opened at GBX 9,903 ($128.91) on Thursday. The firm has a 50-day moving average of £118.91 and a two-hundred day moving average of £121.49. The firm has a market capitalization of £153.50 billion, a PE ratio of 3,143.81, a P/E/G ratio of 0.86 and a beta of 0.17. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 84.97. AstraZeneca has a one year low of GBX 9,461 ($123.16) and a one year high of £133.88 ($174.28).

Insiders Place Their Bets

In related news, insider Michel Demare purchased 2,000 shares of the stock in a transaction dated Friday, September 13th. The shares were acquired at an average cost of GBX 118 ($1.54) per share, for a total transaction of £2,360 ($3,072.12). Insiders own 0.04% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.